Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as GLP-1 receptor agonists, including the popular name brands Ozempic ...

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders. HealthDay News — For people with diabetes, the use of glucagon ...

The GLP-1 medication trend has taken the health and wellness world by storm, largely hailed as a game-changer for weight loss ...

HealthDay News — For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, including ...

Weight loss medications, classified as GLP-1 agonists, stimulate a naturally occurring hormone called GLP-1, which stands for glucagon-like peptide 1. That hormone has several roles, such as ...

as prior studies have reported GLP-1 receptor agonist discontinuation rates of up to 81%, Emanuel's group wrote. They added that the links between weight loss and discontinuation and between ...

Currently, approximately 2% of Americans are prescribed semaglutide, a GLP-1 agonist, underscoring its widespread adoption. Beyond weight loss and diabetes management, emerging research highlights ...

“The rapid evolution of the pharmaceutical industry, particularly in the growing weight loss and diabetes and obesity treatment market, underscores the critical role of innovation and the need ...

The rise of GLP-1 agonist weight loss drugs has prompted the supplement industry to launch a bevy of “natural alternatives” to pharmaceutical compounds like Ozempic and Wegovy. But do they ...

NEW YORK, Jan. 22 (UPI) --As demand for weight-loss injections sold under brand ... The medications are known as glucagon-like peptide-1 receptor agonists (GLP-1RA) and include Mounjaro and ...